Key facts
- OncoC4’s last known valuation is $660.0M (Sep 2025).
- It has raised $50.0M; the latest was Later Stage VC ($50.0M) in Sep 2025.
- Notable investors include National Institutes of Health, 3E Bioventures Capital, Greater Bay Area Homeland, Kaitai Capital.
- OncoC4 has filed 1 Form D with the SEC, most recently Jan 2021 ( sold to 1 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for OncoC4
- ·The full record, as it builds
Funding rounds
No funding rounds for OncoC4 are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OncoC4
Operator of a biopharmaceutical company intended for the discovery of novel biologicals for cancer and neurodegenerative disease treatments. The company develops immunotherapy products targeting cancer evasion of adaptive and innate immunity, enabling healthcare providers to avail drugs that uncouple therapeutic effects and immunotherapy-related adverse effects.
- Sector
- Healthcare
- HQ
- Rockville, MD, United States
- Founded
- 2020
- Employees
- 70
- Website
- oncoc4.com/
- Ownership
- Privately Held (backing)
OncoC4 doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OncoC4 shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OncoC4 in its N-PORT filings yet. We sweep new filings monthly.